Dyadic Reports 2022 Year End Results and Recent Company Progress

Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19

Related Keywords

South Africa ,United States ,India ,Oslo ,Norway ,American ,Mark Emalfarb ,National Institute For Innovation ,Rubic One Health ,Janssen Pharmaceutical Companies Of Johnson ,African Health Products Regulatory Authority ,Foreign Currency Exchange ,Global Food Ingredient Company ,Dyadic International ,Dyadic International Inc ,Phibro Animal Health Corporation ,Securities Exchange ,Third Party ,Phibro Animal Health ,University Of Oslo ,Exchange Commission ,Exchange Commission On ,Company Progress ,Janssen Biotech Inc ,Abic Biological Laboratories Ltd ,Human Health ,Animal Health ,First In Human Phase ,Chief Executive Officer ,Hazelton Dyadic ,Chief Business Officer ,One Health ,Epygen Biotech ,Collaboration Agreement ,Janssen Biotech ,Janssen Pharmaceutical Companies ,National Institute ,Manufacturing Biopharmaceuticals ,White House ,American Rescue Plan ,Serum Albumin ,Bird Flu ,Abic Biological Laboratories ,Abic Agreement ,Reviewed Journals ,Corporate Website ,Currency Exchange ,Non Operating Items ,Toll Free ,Investor Relations ,Securities Act ,Securities Exchange Act ,Ended December ,Consolidated Financial Statements ,Annual Report ,